Masaki Ishigai
- Molecular Biology
- Oncology
- Pharmacology top 5%
- Hematology top 10%
- Radiology, Nuclear Medicine and Imaging
- Co-authors
- Yoshinori AsoNaoaki MuraoMotohiro KatoYasushi ShimonakaHideyuki YasunoKazunari AkiyoshiTakashi NakaiTsuyoshi Shimoboji
- Topics
- Drug Transport and Resistance Mechanisms (14 papers)Pharmacogenetics and Drug Metabolism (11 papers)Monoclonal and Polyclonal Antibodies Research (7 papers)
- Journals
- SHILAP Revista de lepidopterologíaAnalytical BiochemistryJournal of Pharmacology and Experimental Therapeutics
- Partner nations
- United StatesJapanSwitzerland
In The Last Decade
Masaki Ishigai
51 papers receiving 705 citations
Peers
Comparison fields: 5 of 92
- Molecular Biology 254
- Oncology 128
- Pharmacology 122
- Hematology 107
- Radiology, Nuclear Medicine and Imaging 90
Countries citing papers authored by Masaki Ishigai
This map shows the geographic impact of Masaki Ishigai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaki Ishigai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaki Ishigai more than expected).
Fields of papers citing papers by Masaki Ishigai
This network shows the impact of papers produced by Masaki Ishigai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaki Ishigai. The network helps show where Masaki Ishigai may publish in the future.
Co-authorship network of co-authors of Masaki Ishigai
This figure shows the co-authorship network connecting the top 25 collaborators of Masaki Ishigai. A scholar is included among the top collaborators of Masaki Ishigai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaki Ishigai. Masaki Ishigai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 11 | |
| 3 | 14 | |
| 4 | 10 | |
| 5 | 22 | |
| 6 | 21 | |
| 7 | 8 | |
| 8 | 0 | |
| 9 | 11 | |
| 10 | 83 | |
| 11 | 14 | |
| 12 | 22 | |
| 13 | 5 | |
| 14 | 33 | |
| 15 | 8 | |
| 16 | 102 | |
| 17 | 5 | |
| 18 | 17 | |
| 19 | 3 | |
| 20 | 13 |
About Masaki Ishigai
Masaki Ishigai is a scholar working on Pharmacology, Oncology and Spectroscopy, having authored 52 papers that have together received 748 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (14 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). The work is most often cited by research in Pharmacology (122 citations), Hematology (107 citations) and Molecular Medicine (41 citations). Masaki Ishigai has collaborated with scholars based in United States, Japan and Switzerland. Frequent co-authors include Yoshinori Aso, Naoaki Murao, Motohiro Kato, Yasushi Shimonaka, Hideyuki Yasuno, Kazunari Akiyoshi, Takashi Nakai, Tsuyoshi Shimoboji, Kenji Kumaki and Kiyoshi Tatsumi. Their work appears in journals such as SHILAP Revista de lepidopterología, Analytical Biochemistry and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.